Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can rogaine help breast cancer patients keep their hair?

NCT ID NCT05417308

Symptom relief Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early trial tests whether minoxidil (Rogaine) — applied to the scalp or taken as a pill — can help with hair loss caused by hormone therapy in breast cancer patients. About 50 women with stage I-IV breast cancer who report hair thinning since starting endocrine therapy will be enrolled. The study focuses on how well participants stick to the treatment and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Minoxidil (Rogaine)
What this could lead to
If it works, this could offer a way to reduce hair loss from breast cancer hormone therapy, improving quality of life.
What could go wrong
This is a very early, small pilot trial (50 people). It may not show clear benefits, and side effects like skin irritation or unwanted hair growth are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women \>= 18 years of age * Established diagnosis of breast cancer stages I-IV * On endocrine therapy including tamoxifen or aromatase inhibitors with or without concurrent use of ovarian function suppression * Self-reporting hair loss since starting endocrine therapy Exclusion Criteria: * Pregnant or nursing women * Current chemotherapy use or prior chemotherapy use within the last 2 years * History of scarring/cicatricial alopecia or alopecia areata * Prior use of oral or topical minoxidil * Prior or ongoing use of spironolactone * Known sensitivity to minoxidil * Untreated hypothyroidism or iron deficiency as determined by thyroid stimulating hormone (TSH) with reflex free T4 and ferritin level \> 40 to be checked at the time of enrolling if not completed in the 12 months prior

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anatomic stage I breast cancer ajcc V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer endocrine alopecia invasive breast carcinoma metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anatomic stage I breast cancer ajcc V8 Anatomic stage IA breast cancer ajcc V8 Anatomic stage IB breast cancer ajcc V8 Anatomic stage II breast cancer ajcc V8 Anatomic stage IIA breast cancer ajcc V8 Anatomic stage IIB breast cancer ajcc V8 Anatomic stage III breast cancer ajcc V8 Anatomic stage IIIA breast cancer ajcc V8 Anatomic stage IIIB breast cancer ajcc V8 Anatomic stage IIIC breast cancer ajcc V8 Anatomic stage IV breast cancer ajcc V8 Endocrine therapy-induced alopecia Prognostic stage I breast cancer ajcc V8 Prognostic stage IA breast cancer ajcc V8 Prognostic stage IB breast cancer ajcc V8 Prognostic stage II breast cancer ajcc V8 Prognostic stage IIA breast cancer ajcc V8 Prognostic stage IIB breast cancer ajcc V8 Prognostic stage III breast cancer ajcc V8 Prognostic stage IIIA breast cancer ajcc V8 Prognostic stage IIIB breast cancer ajcc V8 Prognostic stage IIIC breast cancer ajcc V8 Prognostic stage IV breast cancer ajcc V8

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.